Literature DB >> 26709222

Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis.

Hai-Ping Zhang1, Jian Zou2, Ping Xie2, Fei Gao3, Hui-Jun Mu4.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and lethal interstitial lung disease with unknown etiology. Divergent observations have suggested that genetic factors contribute to IPF susceptibility. This study investigated the relationship between human leukocyte antigen (HLA), cytokine gene polymorphisms, and IPF in a Chinese Han population. The gene polymorphisms of HLA-A, -B, -DRB1, tumor necrosis factor alpha [TNF-α (-308 A/G)], transforming growth factor beta [TGF-β1 (+869 T/C)], interleukin 10 [IL-10 (-592 C/A, -819 T/C, and -1082 G/A)], and interferon gamma [IFN-γ (+874 T/A)] were detected in 102 individuals with IPF and 266 unrelated normal controls using PCR with sequence-specific primers and a high-resolution melt (HRM) approach. The data showed that there was no difference in HLA allele frequencies between the IPF and control groups. However, the data showed the frequency of HLA-A*02-DRB1*04 haplotype in the IPF group was significantly higher than that in the control group [odds ratio (OR) = 4.69, 95% confidence interval (CI) = 1.82-12.08, p < 0.001]. In addition, no differences in the allele and genotype distributions of the cytokines were found between the IPF and control groups (p > 0.01). Our findings suggest that there is an association between specific HLA haplotype and IPF genetic susceptibility and that the genetic variability of some cytokines may not be involved in the pathogenesis of IPF.
Copyright © 2015. Published by Elsevier Taiwan.

Entities:  

Keywords:  Cytokine; Gene polymorphism; Human leukocyte antigen; Idiopathic pulmonary fibrosis

Mesh:

Substances:

Year:  2015        PMID: 26709222     DOI: 10.1016/j.kjms.2015.10.007

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  7 in total

1.  Specific Donor HLA-DR Types Correlate With Altered Susceptibility to Development of Chronic Lung Allograft Dysfunction.

Authors:  Lynn D Haynes; Walker A Julliard; Joshua D Mezrich; Glen Leverson; Keith C Meyer; William J Burlingham
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 2.  Type 2 macrophages and Th2 CD4+ cells in interstitial lung diseases (ILDs): an overview.

Authors:  Neftali Partida-Zavala; Marco Antonio Ponce-Gallegos; Ivette Buendía-Roldán; Ramcés Falfán-Valencia
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  The association between transforming growth factor beta1 polymorphism and susceptibility to pulmonary fibrosis: A meta-analysis (MOOSE compliant).

Authors:  Lili Xin; Miao Jiang; Guangbao Su; Miao Xie; Hui Chen; Xiao Liu; Muge Xu; Geng Zhang; Jiening Gong
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

4.  Integrative Analysis of Transcriptome-Wide Association Study and mRNA Expression Profiles Identifies Candidate Genes Associated With Idiopathic Pulmonary Fibrosis.

Authors:  Weiming Gong; Ping Guo; Lu Liu; Qingbo Guan; Zhongshang Yuan
Journal:  Front Genet       Date:  2020-12-10       Impact factor: 4.599

Review 5.  Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Xuyi Wu; Yi Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-07-21       Impact factor: 5.988

6.  Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations.

Authors:  Amit Kishore; Veronika Žižková; Lenka Kocourková; Jana Petrkova; Evangelos Bouros; Hilario Nunes; Vladimíra Loštáková; Joachim Müller-Quernheim; Gernot Zissel; Vitezslav Kolek; Demosthenes Bouros; Dominique Valeyre; Martin Petrek
Journal:  Front Immunol       Date:  2016-07-11       Impact factor: 7.561

Review 7.  Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment.

Authors:  Amarpreet Kaur; Susan K Mathai; David A Schwartz
Journal:  Front Med (Lausanne)       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.